Invention Application
WO2008037943A1 CELLS TRANSFORMED WITH NUCLEIC ACID ENCODING NY-ESO T CELL RECEPTORS
审中-公开
用核酸编码NY-ESO T细胞受体的细胞转化
- Patent Title: CELLS TRANSFORMED WITH NUCLEIC ACID ENCODING NY-ESO T CELL RECEPTORS
- Patent Title (中): 用核酸编码NY-ESO T细胞受体的细胞转化
-
Application No.: PCT/GB2006/003649Application Date: 2006-09-29
-
Publication No.: WO2008037943A1Publication Date: 2008-04-03
- Inventor: JAKOBSEN, Bent, Karsten , BOULTER, Jonathan, Michael , LI, Yi , MOLLOY, Peter, Eamon , DUNN, Steven, Mark
- Applicant: MEDIGENE LIMITED , JAKOBSEN, Bent, Karsten , BOULTER, Jonathan, Michael , LI, Yi , MOLLOY, Peter, Eamon , DUNN, Steven, Mark
- Applicant Address: 57C Milton Park Abingdon Oxfordshire OX14 4RX GB
- Assignee: MEDIGENE LIMITED,JAKOBSEN, Bent, Karsten,BOULTER, Jonathan, Michael,LI, Yi,MOLLOY, Peter, Eamon,DUNN, Steven, Mark
- Current Assignee: MEDIGENE LIMITED,JAKOBSEN, Bent, Karsten,BOULTER, Jonathan, Michael,LI, Yi,MOLLOY, Peter, Eamon,DUNN, Steven, Mark
- Current Assignee Address: 57C Milton Park Abingdon Oxfordshire OX14 4RX GB
- Agency: WALLS, Alan, James
- Main IPC: C07K14/705
- IPC: C07K14/705
Abstract:
The present invention provides cells transformed with expressible nucleic acids encoding a TCR specific for the SLLMWITQC-HLA-A*0201 complex, said nucleic acids consisting of: (i) a sequence comprising bases 15 to 836 of SEQ ID Nos: 1, 3, 5, 7, or 9, and (ii) a sequence comprising bases 16 to 948 of SEQ ID Nos: 11, 13, 15, 17, 19, or 21 or; (a) a sequence comprising bases 15 to 836 of SEQ ID Nos: 23, 25, 27, 29 or 31 and (b) a sequence comprising bases 16 to 948 of SEQ ID Nos: 33, 35, 37, 39, 41, or 43. Such cells are useful for targeting NY-ESO + cancer cells presenting the SLLMWITQC-HLA-A*0201 complex.
Information query
